Formulation design of an oral, fast-disintegrating dosage form containing taste-masked particles of famotidine.

A fast-disintegrating dosage form has been developed as a user-friendly formulation that disintegrates in the mouth immediately. Patients can take it without water like a liquid formulation. In this study famotidine taste-masking technology was applied to the new fast-disintegrating tablet in an attempt to produce a novel, taste-masked, fast-disintegrating tablet.

Improvement of HPMC tablet disintegration by the addition of inorganic salts.

Effects of inorganic salts on disintegration of hydroxypropylmethylcellulose (HPMC) matrix tablets have been studied. Adding disintegrants, such as Ac-di-sol, Primojel, Kolidon-CL, or low substituted hydroxypropylcellulose (L-HPC) to HPMC matrix tablets had no effect on disintegration property. Disintegration time was improved by adding NaHCO(3), KH(2)PO(4), K(2)SO(4), KCl, or NaCl to the HPMC tablets as tablet components.

Formulation design of taste-masked particles, including famotidine, for an oral fast-disintegrating dosage form.

In this study, the taste-masking of famotidine, which could apply to any fast-disintegrating tablet, was investigated using the spray-dry method. The target characteristics of taste-masked particles were set as follows: the dissolution rate is not to be more than 30% at 1 min and not less than 85% at 15 min, and the particle size is not to be more than 150 microm in diameter to avoid a gritty feeling in the mouth. The target dissolution profiles of spray-dried particles consisting of Aquacoat ECD30 and Eudragit NE30D or triacetin was accomplished by the screening of formulas and the appropriate lab-scale manufacturing conditions.

Preliminary evaluation of polymer-based drug composite microparticle production by coacervate desolvation with supercritical carbon dioxide.

Drug/polymer particles incorporating phenytoin in polyvinylpyrrolidone (PVP) were prepared by desolvation of coacervates sprayed through an ultrasonic converging-diverging nozzle into supercritical (SC) carbon dioxide. The mean diameter of the particles produced and the crystallinity of phenytoin in the drug/polymer particles were evaluated with an Aerosizer DSP Particle Size Analyzer and powder X-ray diffraction, respectively. The drug release properties from the composite particles were evaluated using the USP 24 Method 2 rotational paddle method with UV detection.

Inhibition of a solid phase reaction among excipients that accelerates drug release from a solid dispersion with aging.

Hydrophobic drug substances can be formulated as a solid dispersion or solution using macromolecular matrices with high glass transition temperatures to attain satisfactory dissolution. However, very few marketed products have previously relied on solid dispersion technology due to physical and chemical instability problems, and processing difficulties. In the present study, a modified release product of a therapeutic drug for hypertension, Barnidipine hydrochloride, was developed.